April 8, 2021: NTRC will present two scientific posters at the virtual AACR Annual Meeting 2021. The figure shows results from one of the posters, demonstrating that erdafitinib-resistant AN3 CA cells have a markedly reduced sensitivity to erdafitinib (left), while they show an increased sensitivity to c-Myc targeting by the bromodomain inhibitor JQ1 (right).
Kinase inhibitor profiling and resistance mechanisms presented at the AACR Annual Meeting 2021
Oss, April 8, 2021 – NTRC will present two scientific posters at the virtual AACR Annual Meeting 2021, which will be opened online on April 10th. The first poster presents the comprehensive biochemical and cellular profiling of all recently approved inhibitors, while the second poster describes the elucidation of resistance mechanisms acquired in vitro in response to the FGFR inhibitor erdafitinib. The posters are available for viewing from April 10th until June 21st for registered attendees through the AACR conference website.
Poster #1: Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 – Poster no. 1480
Between 2018 and 2020, twenty kinase inhibitors have been approved by the FDA for oncology indications. Even though multiple inhibitors might act on the same primary target, selectivity and potency can vary substantially between inhibitors. The poster presents extensive cancer cell line and kinase panel profiling of the twenty newly-approved kinase inhibitors and nineteen inhibitors acting on the same primary target. The presented work can aid in selecting the most suitable kinase inhibitor for a specific indication and finding new applications for EGFR, FGFR, and TRK inhibitors.
Poster #2: Altered response to BET bromodomain inhibitors JQ1 and I-BET-762 targeting c-Myc in erdafitinib-resistant endometrial carcinoma cell line AN3 CA – Poster no. 1080
Cancer cells can develop resistance to escape from kinase inhibitor treatment. Insight into the acquired resistance mechanisms is therefore crucial to determine the second line treatment. The work presented in this poster elucidates the resistance mechanisms that cancer cell lines develop in vitro to the FGFR kinase inhibitor erdafitinib. Furthermore, it provides insight into inhibitors that are of potential use for treatment of erdafitinib-resistant cancers.
The posters will also be available for download from our website: Poster #1 and Poster #2 (available from April 10, 2021).
NTRC is a precision medicine company dedicated to discovering new anti cancer drug candidates. We help you to find a mechanistic hypothesis before entering the clinic. We can study a wide range of cancer cells, primary patient material and immune cells in vitro, in isolation and in coculture, after exposure to monotherapy and combination therapy. In addition, we perform in-depth mechanistic analyses in cells and by biophysical methods, such as Biacore and LC-MS/MS. Keywords are: Quality. Flexibility. Short Turnaround Time.